Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 61 to 75 of 138 results for sclerosis

  1. Tolebrutinib for treating primary progressive multiple sclerosis [TSID12166]

    Topic prioritisation

  2. ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot (MIB56)

    NICE has developed a medtech innovation briefing (MIB) on the ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot

  3. Autologous unmanipulated peripheral blood stem cell therapy for multiple sclerosis

    Topic prioritisation

  4. Faecal incontinence in adults: management (CG49)

    This guideline covers assessing and managing faecal incontinence (any involuntary loss of faeces that is a social or hygienic problem) in people aged 18 and over. It aims to ensure that staff are aware that faecal incontinence is a sign or a symptom, not a diagnosis. It aims to improve the physical and mental health and quality of life of people with faecal incontinence.

  5. Subcutaneous ocrelizumab for treating primary progressive or relapsing multiple sclerosis [TSID11895]

    Topic prioritisation

  6. Can vitamin D slow down the progression of disability in Multiple Sclerosis (MS)?

    Can vitamin D slow down the progression of disability in Multiple Sclerosis (MS)? Any explanatory notes(if applicable) Despite...

  7. NICE recommends the development of patient registries for multiple sclerosis to capture long-term treatment-related outcomes.

    NICE recommends the development of patient registries for multiple sclerosis to capture long-term treatment-related outcomes. Any...

  8. Neuropathic pain in adults: pharmacological management in non-specialist settings (CG173)

    This guideline covers managing neuropathic pain (nerve pain) with pharmacological treatments (drugs) in adults in non-specialist settings. It aims to improve quality of life for people with conditions such as neuralgia, shingles and diabetic neuropathy by reducing pain and promoting increased participation in all aspects of daily living. The guideline sets out how drug treatments for neuropathic pain differ from traditional pain management.

  9. What is the clinical and cost effectiveness of cognitive rehabilitation for people with Multiple sclerosis (MS)?

    cost effectiveness of cognitive rehabilitation for people with Multiple sclerosis (MS)? Any explanatory notes(if applicable) Cognitive...

  10. What non-pharmacological interventions are effective in reducing spasticity in people with Multiple Sclerosis (MS)?

    interventions are effective in reducing spasticity in people with Multiple Sclerosis (MS)? Any explanatory notes(if applicable)...

  11. Multiple long-term conditions: medication review (IND207)

    This indicator covers the percentage of patients with moderate or severe frailty and/or multimorbidity who have received a medication review in the last 12 months which is structured, has considered the use of a recognised tool and taken place as a shared discussion. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM186

  12. What is the optimal frequency, intensity and form of rehabilitation for mobility problems in people with Multiple Sclerosis (MS)?

    and form of rehabilitation for mobility problems in people with Multiple Sclerosis (MS)? Any explanatory notes(if applicable) Reduced...

  13. Stereotactic radiosurgery for trigeminal neuralgia (IPG715)

    Evidence-based recommendations on stereotactic radiosurgery for trigeminal neuralgia in adults. This involves focusing radiation on the trigeminal nerve to damage it, thereby relieving pain.

  14. Amyotrophic lateral sclerosis - SAR443820 [ID6386]

    Discontinued Reference number: GID-TA11476